Limited value of genetic profiling in guiding radioiodine therapy for metastatic differentiated thyroid cancer.

doi:10.1530/ERC-24-0298

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Limited value of genetic profiling in guiding radioiodine therapy for metastatic differentiated thyroid cancer.

Endocrine-related cancer - 1 May 2025

He Ziyan, Wang Congcong, Liu Chang, Zhang Ke, Wang Junyao, Wang Xufu, Zhang Yifan, Chen Libo

Abstract excerpt

Assessing the 131I-avidity of metastatic differentiated thyroid cancer (mDTC) is pivotal to characterizing the nature of disease and optimizing the therapeutic strategy. In this prospective study, the predictive value of genetic profiling of 18 selected thyroid cancer-relevant genes for 131I-avidity and the response to radioiodine therapy (RT) was studied in comparison with those of diagnostic 131I scan. During...

Read the complete abstract on PubMed

Topics

Humans
Iodine Radioisotopes
Thyroid Neoplasms
Female
Male
Middle Aged
Adult

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Proto-Oncogene Proteins B-raf

Aged

Prospective Studies

Genetic Profile

Telomerase

Mutation

Young Adult

Source

Open in PubMed

Identifiers

PMID: 40100701
DOI: 10.1530/ERC-24-0298

Genes

BRAF
TERT

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Limited value of genetic profiling in guiding radioiodine therapy for metastatic differentiated thyroid cancer.PMID 40100701Read ↗

Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid Cancer.Semantic proximity Read ↗

Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study.Semantic proximity Read ↗

Dynamic phenotyping of radioiodine-refractory differentiated thyroid cancer: thyroglobulin trajectories, dual-modal imaging, and genotype-defined treatment resistance.Semantic proximity Read ↗

Non-Iodine-Avid Disease Is Highly Prevalent in Distant Metastatic Differentiated Thyroid Cancer With Papillary Histology.Semantic proximity Read ↗

Positive BRAFV600E mutation of primary tumor influences radioiodine avidity but not prognosis of papillary thyroid cancer with lung metastases.Semantic proximity Read ↗

Effect of BRAFV600E and TERT Promoter Mutations on Thyroglobulin Response in Patients With Distant-Metastatic Differentiated Thyroid Cancer.Semantic proximity Read ↗

The Genetic Duet of BRAF V600E and TERT Promoter Mutations Robustly Predicts Loss of Radioiodine Avidity in Recurrent Papillary Thyroid CancerSemantic proximity Read ↗

Molecular Profile of Advanced Radioiodine-refractory Thyroid Cancer and Response to Lenvatinib Treatment.Semantic proximity Read ↗

Restoring Radioiodine Avidity in Radioiodine-refractory Differentiated Thyroid Cancer With Genotype-guided MAPK Inhibition and Dosimetry-guided Radioiodine.Semantic proximity Read ↗

Relationship between clinicopathologic factors and FDG avidity in radioiodine-negative recurrent or metastatic differentiated thyroid carcinoma.Semantic proximity Read ↗

Association between clinical and pathological factors and risk of radioiodine refractory in patients with differentiated thyroid carcinoma.Semantic proximity Read ↗

The Correlation Between the Presence of BRAFV600E and TERT Promoter Mutation and the Response to Treatment with Iodine 131 in Differentiated Thyroid Cancer Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.